Annual report pursuant to Section 13 and 15(d)

EQUTY INVESTMENT (Details Narrative)

v3.20.1
EQUTY INVESTMENT (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Dec. 18, 2018
Dec. 31, 2019
SHARE OF NET LOSSES OF EQUITY METHOD INVESTEE   $ (604,000)
Equity Method Goodwill   5,041,000
ILiAD [Member]    
Advisory and legal expenses   $ 41,000
ILiAD [Member] | Warrant [Member]    
Units purchase   366,666
Price per unit   $ 2.75
ILiAD [Member] | Tranche One [Member]    
Initial investment $ 2,500,000  
Description for the terms of allowed-to-proceed notice under aggrement May 2, 2019 that it had received an “allowed to proceed” notice from the FDA permitting ILiAD to advance to the Phase 2b clinical study of its BP2E1 vaccine. ILiAD elected to permit its Class C investors (including the Company) to bifurcate their tranche 2 commitment such that 40% would be currently due ($1,000,000 paid by the Company on May 6, 2019) and 60% (additional $1,500,000 investment by the Company) would be due when ILiAD received satisfactory safety data from the clinical study. On August 9, 2019, ILiAD notified us that the FDA has allowed Phase 2b trial to proceed to full enrollment based on satisfactory safety data from the first phase of the clinical study which triggered our additional $1,500,000 investment. The Phase 2b trial is fully enrolled and preliminary immunological data is anticipated to be received by ILiAD by April 2020. At December 31, 2019, we owned approximately 10.3% of the outstanding units of ILiAD (on a non-fully diluted basis).  
ILiAD [Member] | Tranche Two [Member]    
Initial investment $ 2,500,000
ILiAD [Member] | Class C units [Member]    
Ownership percentage   10.30%
ILiAD [Member] | Class C units [Member] | Tranche One [Member]    
Units purchase   1,111,111
Price per unit   $ 2.25
ILiAD [Member] | Class C units [Member] | Tranche Two [Member]    
Units purchase 943,396  
Price per unit $ 2.65  
Warrants to purchase units 311,320  
Exercise price $ 3.50  
ILiAD [Member] | Maximum [Member]    
Investment $ 5,000,000  
ILiAD [Member] | Maximum [Member] | Class C units [Member]    
Investment $ 14,500,000